Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis' Galvus NDA Follows Close On The Heels Of Merck's Januvia

This article was originally published in The Pink Sheet Daily

Executive Summary

The likely late November user fee date for Novartis' DPP-IV inhibitor vildagliptin is mere weeks behind that for sitagliptin.

You may also be interested in...



Galvus Review Delayed For Safety Analysis Of Primate Skin Data

FDA pushes the user fee for the DPP-4 inhibitor back until the end of February.

Galvus Review Delayed For Safety Analysis Of Primate Skin Data

FDA pushes the user fee for the DPP-4 inhibitor back until the end of February.

Galvus Trial May Show Potential For Modifying Type 2 Diabetes Treatment Guidelines

Novartis initiates 7,500-patient head-to-head trial investigating the DPP-IV inhibitor compared to thiazolidinediones.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS063936

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel